DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.

MLA

Ma, Juan, et al. “DNMT3A Co-Mutation Is Required for FLT3-ITD as an Adverse Prognostic Indicator in Intermediate-Risk Cytogenetic Group AML.” Leukemia & Lymphoma, vol. 59, no. 8, Aug. 2018, pp. 1938–48. EBSCOhost, https://doi.org/10.1080/10428194.2017.1397659.

APA

Ma, J., Dunlap, J., Paliga, A., Traer, E., Press, R., Shen, L., & Fan, G. (2018). DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML. Leukemia & Lymphoma, 59(8), 1938–1948. https://doi.org/10.1080/10428194.2017.1397659

Chicago

Ma, Juan, Jennifer Dunlap, Aleksandra Paliga, Elie Traer, Richard Press, Lisong Shen, and Guang Fan. 2018. “DNMT3A Co-Mutation Is Required for FLT3-ITD as an Adverse Prognostic Indicator in Intermediate-Risk Cytogenetic Group AML.” Leukemia & Lymphoma 59 (8): 1938–48. doi:10.1080/10428194.2017.1397659.